XNAS
BNKK
Market cap169mUSD
Oct 08, Last price
1.43USD
1D
-2.05%
1Q
16.26%
IPO
-76.17%
Name
Jupiter Wellness Inc
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Jupiter Wellness, Inc. specializes in the development of therapeutic and wellness products derived from cannabidiol (CBD). Its clinical development portfolio features several innovative candidates, such as CaniDermRX (JW-100), a unique topical blend of CBD and aspartame aimed at addressing eczema, dermatitis, and actinic keratosis. Also in development are JW-101, a prescription solution designed for burn treatment, and JW-200, an over-the-counter lotion or lip balm formulated to alleviate symptoms associated with cold sores. Beyond its clinical efforts, Jupiter Wellness also manufactures, distributes, and markets a range of consumer goods. These include CBD-enriched sunscreens sold under the CaniSun label, CBD-infused skincare lotions marketed as CaniSkin, and a selection of dermatological remedies for pain and inflammation offered through its CaniDermRX brand. Established in 2018, the company, formerly known as CBD Brands, Inc., maintains its headquarters in Jupiter, Florida.
Key people
John Gulyas
Independent Chairman of the Board · since 2024
Danielle De Rosa
Chief Financial Officer · since 2024
David Sandler
Chief Operating Officer · since 2024
Jarrett Boon
Chief Executive Officer, Director · since 2024
Stacey Duffy
Director · since 2025
Todd Gibson
Director · since 2025
Connor Klein
Director · since 2025
Mitchell Rudy
Director · since 2025
David Long
Independent Director · since 2024
James McAvity
Independent Director · since 2025
Independent Director · since 2019
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | |
| Income | ||||||||
Revenues | ||||||||
Cost of revenue | ||||||||
Unusual Expense (Income) | ||||||||
NOPBT | ||||||||
NOPBT Margin | ||||||||
Operating Taxes | ||||||||
Tax Rate | ||||||||
NOPAT | ||||||||
Net income | ||||||||
Dividends | ||||||||
Dividend yield | ||||||||
Proceeds from repurchase of equity | ||||||||
BB yield | ||||||||
| Debt | ||||||||
Debt current | ||||||||
Long-term debt | ||||||||
Deferred revenue | ||||||||
Other long-term liabilities | ||||||||
Net debt | ||||||||
| Cash flow | ||||||||
Cash from operating activities | ||||||||
CAPEX | ||||||||
Cash from investing activities | ||||||||
Cash from financing activities | ||||||||
FCF | ||||||||
| Balance | ||||||||
Cash | ||||||||
Long term investments | ||||||||
Excess cash | ||||||||
Stockholders' equity | ||||||||
Invested Capital | ||||||||
ROIC | ||||||||
ROCE | ||||||||
| EV | ||||||||
Common stock shares outstanding | ||||||||
Price | ||||||||
Market cap | ||||||||
EV | ||||||||
EBITDA | ||||||||
EV/EBITDA | ||||||||
Interest | ||||||||
Interest/NOPBT | ||||||||